Sana Biotechnology, Inc. Debt Securities, Available-for-sale, Unrealized Loss Position
Sana Biotechnology, Inc. (SANA) had Debt Securities, Available-for-sale, Unrealized Loss Position of $9.13 million as of 2024-09-30, per its 10-Q filed 2024-11-08.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2024-11-08
- 2024-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $9.13M.
- 2024-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $86.41M.
- 2024-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $125.35M.
- 2023-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $20.97M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2024-09-30 | $9.13M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $86.41M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $125.35M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $20.97M 10-Q · filed 2024-11-08 |
| 2023-09-30 | $48.53M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $97.02M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $172.03M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $255.09M 10-K · filed 2024-02-29 |
| 2022-09-30 | $352.74M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $424.95M 10-Q · filed 2022-08-04 |
| 2021-12-31 | $486.55M 10-K · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |